Repetitive Transcranial Magnetic Stimulation in Fibromyalgia (STIMALGI)

• Change from baseline in pain Visual Analog Scale (VAS) at 14 weeks of treatment [ Time Frame: Daily average VAS at baseline, week 2, week 4, week 8, week 14 ] [ Designated as safety issue: No ]
  Patient will note down each day the VAS for the last 24 hours.
  
  

• Change from base line in quality of life at 14 weeks and 26 weeks [ Time Frame: At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program ] [ Designated as safety issue: No ]
  Fibromyalgia Impact Questionnaire (FIQ)
  
  
• Change from base line in depression assessment at 14 weeks and 26 weeks [ Time Frame: at the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program ] [ Designated as safety issue: No ]
  Beck Depression Inventory (BDI)
  
  
• Change from baseline in Covi's anxiety scale [ Time Frame: at the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program ] [ Designated as safety issue: No ]
  Covi's anxiety scale
  
  
• Change from baseline in sleep quality at 14 weeks abd 26 weeks [ Time Frame: At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program ] [ Designated as safety issue: No ]
  Number of times awaking at night
  
  
• Change from baseline in neuromuscular fatigability at 14 weeks and 26 weeks [ Time Frame: At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program ] [ Designated as safety issue: No ]
  Maximal voluntary activation level
  
  
• Change from baseline in cardiac variability at 14 weeks and 26 weeks [ Time Frame: At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program ] [ Designated as safety issue: No ]
  RMSSD values, power of spectral density HF, KF, LF/HF, alpha index (baroreflex sensitivity)
  
  
• Evolution of the analgesic effect after the end of the program [ Time Frame: Daily average VAS at the end (14 weeks) and 26 weeks after the end of the program ] [ Designated as safety issue: No ]
  Patient will note down each day the VAS for the last 24 hours.
  
  

Fibromyalgia is the most frequent chronic diffuse painful disease (3 to 4% of the general population).

Analgesic drugs are widely used in fibromyalgia, pain being the main symptom. However the effectiveness of analgesic drugs is often insufficient.

Among non-drug therapies, rehabilitation exercise plays an important role with a special interest in terms of the quality of life, strain and pain.

More recently the Transcranial Magnetic Stimulation effects have been evaluated in patients suffering from fibromyalgia with a statistically significative analgesic effect.

Both rehabilitation exercise and Transcranial Magnetic Stimulation (rTMS) have shown their respective analgesic effectiveness in fibromyalgia. It now seems important to evaluate the combination of these two therapies.

Main objective: To evaluate the analgesic effect of rTMS in fibromyalgia patients doing rehabilitation exercise.

Primary endpoint:

The evaluation methode used is a visual analog scale (VAS) of pain. Patients will note down every day VAS of over the last 24 hours.

The evolution of the VAS during the treatment period with respect to baseline, will be compared in both groups, active rTMS and placebo rTMS.

The investigators will analyze the average daily VAS for different weeks (W2, W4, W8, W14) compared to the average daily VAS at the baseline.

After a baseline period of 15 days, patients will begin sessions of rTMS and rehabilitation exercise for a period of 14 weeks.

The study is composed of three assessment visits : a baseline visit, a visit corresponding to the end of the therapy with exercise period and a last assessment visit at 26 weeks after the end of the treatment.

These visits will include clinical examination, blood test, an effort test, an orthostatic test, a resistance to fatigue test and polysomnography.